Sphingosine 1 phosphate agonists (SPI): A potential agent to prevent acute lung injury in COVID-19

Sepideh Zununi Vahed; Shahram Ghiyasvand; Seyed Mahdi Hosseiniyan Khatibi; Bhargav Patel; Mohammadali Mohajel Shoja; Ramin Tolouian; Mohammadreza Ardalan

doi:10.34172/ipp.2021.03

Sphingosine 1 phosphate agonists (SPI): A potential agent to prevent acute lung injury in COVID-19

Sepideh Zununi Vahed
, Shahram Ghiyasvand
, Seyed Mahdi Hosseiniyan Khatibi
, Bhargav Patel
, Mohammadali Mohajel Shoja
, Ramin Tolouian
, Mohammadreza Ardalan

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

SARS-CoV-2 is a worldwide pandemic, that has led to the morbidity and mortality of millions of people. This virus rapidly proliferates and destroys lung epithelial cells directly, which is worsened by a subsequent cytokine storm. This cytokine storm diffusely damages the alveolar barriers and leads to fibrin and fluid exudation, hyaline membrane formation, and infiltration of inflammatory cells into the lung causing acute respiratory distress syndrome (ARDS). To date, there exists no medication to treat SARS-CoV-2 infection and novel new therapeutics are still being explored to prevent or limit the damage to the lung. Sphingosine 1-phosphate (S1P) is an effective bioactive lipid mediator and its related signaling pathways are vital for endothelial cell integrity. Stabilizing the pulmonary endothelial barrier and decreasing the inflammatory infiltrate by S1P analogs such as Fingolimod (FTY720-P) would be a new therapeutic approach for the hindrance of pulmonary exudation and subsequent ARDS.

Original language	English
Article number	e03
Journal	Immunopathologia Persa
Volume	7
Issue number	1
DOIs	https://doi.org/10.34172/ipp.2021.03
State	Published - Jan 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
Copyright © 2021 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ASJC Scopus Subject Areas

Endocrinology, Diabetes and Metabolism
Immunology
Hematology
Immunology and Microbiology (miscellaneous)

Keywords

Acute respiratory distress syndrome
COVID-19
Cytokine storm
FTY720-P
Fingolimod
SARS-CoV-2

Access to Document

10.34172/ipp.2021.03

Cite this

@article{d2eb92960680463ebb8aad9f97ef5a83,

title = "Sphingosine 1 phosphate agonists (SPI): A potential agent to prevent acute lung injury in COVID-19",

abstract = "SARS-CoV-2 is a worldwide pandemic, that has led to the morbidity and mortality of millions of people. This virus rapidly proliferates and destroys lung epithelial cells directly, which is worsened by a subsequent cytokine storm. This cytokine storm diffusely damages the alveolar barriers and leads to fibrin and fluid exudation, hyaline membrane formation, and infiltration of inflammatory cells into the lung causing acute respiratory distress syndrome (ARDS). To date, there exists no medication to treat SARS-CoV-2 infection and novel new therapeutics are still being explored to prevent or limit the damage to the lung. Sphingosine 1-phosphate (S1P) is an effective bioactive lipid mediator and its related signaling pathways are vital for endothelial cell integrity. Stabilizing the pulmonary endothelial barrier and decreasing the inflammatory infiltrate by S1P analogs such as Fingolimod (FTY720-P) would be a new therapeutic approach for the hindrance of pulmonary exudation and subsequent ARDS.",

keywords = "Acute respiratory distress syndrome, COVID-19, Cytokine storm, FTY720-P, Fingolimod, SARS-CoV-2",

author = "Vahed, \{Sepideh Zununi\} and Shahram Ghiyasvand and Khatibi, \{Seyed Mahdi Hosseiniyan\} and Bhargav Patel and Shoja, \{Mohammadali Mohajel\} and Ramin Tolouian and Mohammadreza Ardalan",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.",

year = "2021",

month = jan,

doi = "10.34172/ipp.2021.03",

language = "English",

volume = "7",

journal = "Immunopathologia Persa",

issn = "2423-8015",

publisher = "Nickan Research Institute",

number = "1",

}

TY - JOUR

T1 - Sphingosine 1 phosphate agonists (SPI)

T2 - A potential agent to prevent acute lung injury in COVID-19

AU - Vahed, Sepideh Zununi

AU - Ghiyasvand, Shahram

AU - Khatibi, Seyed Mahdi Hosseiniyan

AU - Patel, Bhargav

AU - Shoja, Mohammadali Mohajel

AU - Tolouian, Ramin

AU - Ardalan, Mohammadreza

N1 - Publisher Copyright: Copyright © 2021 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PY - 2021/1

Y1 - 2021/1

N2 - SARS-CoV-2 is a worldwide pandemic, that has led to the morbidity and mortality of millions of people. This virus rapidly proliferates and destroys lung epithelial cells directly, which is worsened by a subsequent cytokine storm. This cytokine storm diffusely damages the alveolar barriers and leads to fibrin and fluid exudation, hyaline membrane formation, and infiltration of inflammatory cells into the lung causing acute respiratory distress syndrome (ARDS). To date, there exists no medication to treat SARS-CoV-2 infection and novel new therapeutics are still being explored to prevent or limit the damage to the lung. Sphingosine 1-phosphate (S1P) is an effective bioactive lipid mediator and its related signaling pathways are vital for endothelial cell integrity. Stabilizing the pulmonary endothelial barrier and decreasing the inflammatory infiltrate by S1P analogs such as Fingolimod (FTY720-P) would be a new therapeutic approach for the hindrance of pulmonary exudation and subsequent ARDS.

AB - SARS-CoV-2 is a worldwide pandemic, that has led to the morbidity and mortality of millions of people. This virus rapidly proliferates and destroys lung epithelial cells directly, which is worsened by a subsequent cytokine storm. This cytokine storm diffusely damages the alveolar barriers and leads to fibrin and fluid exudation, hyaline membrane formation, and infiltration of inflammatory cells into the lung causing acute respiratory distress syndrome (ARDS). To date, there exists no medication to treat SARS-CoV-2 infection and novel new therapeutics are still being explored to prevent or limit the damage to the lung. Sphingosine 1-phosphate (S1P) is an effective bioactive lipid mediator and its related signaling pathways are vital for endothelial cell integrity. Stabilizing the pulmonary endothelial barrier and decreasing the inflammatory infiltrate by S1P analogs such as Fingolimod (FTY720-P) would be a new therapeutic approach for the hindrance of pulmonary exudation and subsequent ARDS.

KW - Acute respiratory distress syndrome

KW - COVID-19

KW - Cytokine storm

KW - FTY720-P

KW - Fingolimod

KW - SARS-CoV-2

UR - https://www.scopus.com/pages/publications/85105041326

UR - https://www.scopus.com/pages/publications/85105041326#tab=citedBy

U2 - 10.34172/ipp.2021.03

DO - 10.34172/ipp.2021.03

M3 - Article

AN - SCOPUS:85105041326

SN - 2423-8015

VL - 7

JO - Immunopathologia Persa

JF - Immunopathologia Persa

IS - 1

M1 - e03

ER -

Sphingosine 1 phosphate agonists (SPI): A potential agent to prevent acute lung injury in COVID-19

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this